Costs of administration, travelling, and productivity losses associated with hospital administration of multiple myeloma drugs in Finland.

CONCLUSIONS: The administration of intravenous or subcutaneous PIs to treat MM in health care facilities causes significant and potentially avoidable health care, travelling and indirect costs and they should be included in all health economic evaluations (HEEs). As the cost estimates utilized in this study represent most of central hospitals in the country, they provide useful information for future HEEs. A broader conclusion is that novel oral medications, such as the first oral PI, have a significant potential for reducing administration-related costs of subcutaneous or intravenous PIs. PMID: 30644325 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research